Hengrui secures clinical trial approvals for multiple oncology drugs

Jiangsu Hengrui Medicine and its subsidiaries have received approval from the National Medical Products Administration for clinical trials of four oncology drugs: SHR-8068 injection, adebrelimab injection, bevacizumab injection, and apatinib mesylate tablets.

The trials will investigate intravenous SHR-8068 in combination with anti-tumor drugs for colorectal cancer patients. The company has invested heavily in R&D across these candidates: CNY 21.35 billion for SHR-8068, CNY 88.65 billion for adebrelimab, CNY 34.49 billion for bevacizumab, and CNY 58.67 billion for apatinib mesylate tablets.